Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Filip Janku Sells 6,000 Shares of Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) insider Filip Janku sold 6,000 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $22.95, for a total value of $137,700.00. Following the transaction, the insider directly owned 59,992 shares in the company, valued at $1,376,816.40. The trade was a 9.09% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Filip Janku also recently made the following trade(s):

• On Tuesday, June 23rd, Filip Janku sold 11,845 shares of Monte Rosa Therapeutics stock. The shares were sold at an average price of $20.22, for a total value of $239,505.90.
• On Wednesday, June 24th, Filip Janku sold 30,000 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $21.42, for a total transaction of $642,600.00.

Monte Rosa Therapeutics Stock Up 1.3%

NASDAQ:GLUE traded up $0.30 during mid-day trading on Tuesday, reaching $24.20. The company’s stock had a trading volume of 2,334,415 shares, compared to its average volume of 1,373,686. Monte Rosa Therapeutics, Inc. has a 1 year low of $4.12 and a 1 year high of $25.77. The stock has a fifty day moving average of $19.06 and a 200-day moving average of $18.69. The firm has a market capitalization of $2.04 billion, a PE ratio of -16.35 and a beta of 1.60.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. The business had revenue of $4.21 million for the quarter, compared to analysts’ expectations of $10.95 million. On average, analysts expect that Monte Rosa Therapeutics, Inc. will post -1.23 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Weiss Ratings upgraded Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, May 11th. Guggenheim boosted their price target on Monte Rosa Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday. Wells Fargo & Company decreased their price objective on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research note on Wednesday, March 18th. Finally, Wall Street Zen downgraded Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Monte Rosa Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $33.33.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in GLUE. State Street Corp raised its stake in Monte Rosa Therapeutics by 148.9% in the fourth quarter. State Street Corp now owns 2,107,480 shares of the company’s stock valued at $33,045,000 after buying an additional 1,260,707 shares during the last quarter. MPM Bioimpact LLC purchased a new stake in shares of Monte Rosa Therapeutics during the fourth quarter worth about $18,399,000. AQR Capital Management LLC grew its stake in shares of Monte Rosa Therapeutics by 459.4% during the second quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock worth $5,791,000 after acquiring an additional 1,054,406 shares during the last quarter. Braidwell LP acquired a new position in shares of Monte Rosa Therapeutics during the fourth quarter valued at about $14,870,000. Finally, Vestal Point Capital LP purchased a new position in shares of Monte Rosa Therapeutics in the 3rd quarter valued at approximately $5,928,000. 79.96% of the stock is owned by institutional investors and hedge funds.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.